Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone

Kwee Yong; Thomas Martin; Meletios-Athanasios Dimopoulos; Joseph Mikhael; Marcelo Capra; Thierry Facon; Roman Hajek; Ivan Špička; Ross Baker; Kihyun Kim; Gracia Martinez; Chang-Ki Min; Ludek Pour; Xavier Leleu; Albert Oriol; Youngil Koh; Kenshi Suzuki; France Casca; Sandrine Macé; Philippe Moreau

doi:10.1080/14796694.2026.2683336

Back

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone

Journal article

Open access

Peer reviewed

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone

Kwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, …

Future oncology (London, England), Vol.22(15), pp.1737-1749

2026

DOI: https://doi.org/10.1080/14796694.2026.2683336

PMID: 42363804

Files and links (1)

pdf

Published4.09 MBDownload View

Open Access CC BY-NC-ND V4.0

Abstract

isatuximab

multiple myeloma

oncology

plain language summary

carfilzomib

(27 Jun 2026): Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone, Future Oncology,

Details

Title: Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone
Authors/Creators: Kwee Yong - London Cancer
Thomas Martin - University of California, San Francisco
Meletios-Athanasios Dimopoulos - National and Kapodistrian University of Athens
Joseph Mikhael - Translational Genomics Research Institute
Marcelo Capra - Hospital Mãe de Deus
Thierry Facon - Lille’s Cardiology Hospital
Roman Hajek - University of Ostrava
Ivan Špička - Charles University
Ross Baker - Murdoch University
Kihyun Kim - Samsung Medical Center
Gracia Martinez - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Chang-Ki Min - The Catholic University of Korea Seoul St. Mary's Hospital
Ludek Pour - University Hospital Brno
Xavier Leleu - Inserm
Albert Oriol - Institut Català d'Oncologia
Youngil Koh - Seoul National University Hospital
Kenshi Suzuki - Japanese Red Cross Medical Center
France Casca - Honeywell (France)
Sandrine Macé - Sanofi (France)
Philippe Moreau - Hotel Dieu Hospital
Publication Details: Future oncology (London, England), Vol.22(15), pp.1737-1749
Publisher: Taylor & Francis
Identifiers: 991005897387907891
Murdoch Affiliation: Centre for Molecular Medicine and Innovative Therapeutics
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: SDGs in the Output

Metrics

1 Record Views